erlotinib hydrochloride has been researched along with Kidney Failure, Chronic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
Galetta, D; Gridelli, C; Maione, P; Rossi, A | 1 |
2 other study(ies) available for erlotinib hydrochloride and Kidney Failure, Chronic
Article | Year |
---|---|
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2007 |